Peptides split into two groups that share only the name. At one end sit approved, tested peptide drugs: the GLP-1 medicines that produce large weight loss and cut heart attacks, and insulin before them. At the other sit BPC-157, TB-500, growth-hormone peptides, and melanotan, sold online for healing and anti-aging. These are experimental compounds, most resting on animal data, and none is an approved drug.
What is true of one group says nothing about the other. The approved peptides come through a clinician and a pharmacy. The rest are unapproved, unverified, and injected, a very different proposition.
Findings & Outcomes
What It Is
A peptide is a short chain of amino acids, the same building blocks that make a protein, only fewer of them. The body runs on peptides as signaling molecules: insulin manages blood sugar, and GLP-1 controls appetite and the release of insulin. Both are peptide hormones. The word now covers two groups. One is a small set of approved, tested drugs. The other is a large, growing set of compounds sold online to heal injuries, build muscle, and slow aging. Most of the second group never passed a proper human trial, and they are made and sold outside any medical system.
Anatomy
1The approved peptides
A few peptides are approved, tested medicines. GLP-1 drugs like semaglutide, and insulin before them, are peptide hormones made to pharmaceutical standard and prescribed for defined conditions. They carry strong trial evidence.
2The research peptides
BPC-157, TB-500, and the growth hormone peptides such as CJC-1295 and ipamorelin are sold online for healing, muscle, and anti-aging. They are experimental, and none is an approved drug.
3The risky and cosmetic edges
Melanotan, injected to tan the skin, has caused serious harm in reported cases. Copper peptides in skincare sit at the low-stakes cosmetic end. Most of the injectable products in between come from a grey market.
What It Does
The approved peptides carry some of the strongest trial evidence in this whole section. In large randomized trials, semaglutide cut about 15% of body weight over 68 weeks. The newer dual peptide tirzepatide reached about 21% at its top dose. The same drugs lower blood sugar in type 2 diabetes. In people with obesity and heart disease, semaglutide cut major cardiovascular events by about a fifth. For excess weight and metabolic disease, losing weight and lifting are the first levers. The GLP-1 drugs are the approved option when the real thing is out of reach. These approved drugs, the same ones driving today's weight and metabolic health treatment, show that a peptide can change a person's health.
The online peptides have no comparable evidence. BPC-157 and TB-500 rest on healing research done almost entirely in rats or in cell and animal models, with no completed randomized human trial behind either. Growth hormone peptides such as CJC-1295 do reliably raise growth hormone and IGF-1 in the blood, but the studies stop at the blood marker. No human trial shows they build muscle, cut fat, speed recovery, or slow aging. Copper peptides in skincare act on skin-repair pathways in the lab and rest on thin human cosmetic data.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Weight And Fat Loss
Semaglutide, a GLP-1 peptide, cut body weight about 15% in a 68-week trial
Semaglutide is a GLP-1 peptide, and as a prescription drug it produces large, reliable weight loss, around 15% of body weight in a big randomized trial. This is the approved end of the peptide category, separate from the injectable powders sold online.
Wilding and colleagues (2021) randomized 1,961 adults with overweight or obesity and without diabetes to once-weekly semaglutide 2.4 mg or placebo, both with lifestyle support, for 68 weeks. Mean change in body weight was -14.9% with semaglutide versus -2.4% with placebo, and improvements were seen in waist circumference, blood pressure and metabolic markers. Gastrointestinal effects, mostly nausea and diarrhea, were the common reason for stopping. Semaglutide is a peptide analogue of the gut hormone GLP-1 and is a licensed medicine, distinct from the research peptides sold without a prescription.
Who this may not transfer to:Studied in adults with overweight or obesity, majority women; the effect is specific to the licensed drug under medical supervision and does not transfer to unregulated peptides.
This shows what an approved peptide drug can do under medical supervision. It says nothing about the safety or value of the anti-aging and fitness peptides sold online, which are a separate group with far weaker evidence.
The study · 1
Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity · N Engl J Med 2021;384(11):989-1002
Tirzepatide cut body weight about 21% at the top dose over 72 weeks
Tirzepatide, a dual GIP and GLP-1 peptide, is the most effective approved weight-loss drug so far, taking off about 21% of body weight at the top dose in a large randomized trial. Like semaglutide it is a prescription medicine, not one of the peptides sold online.
Jastreboff and colleagues (2022, SURMOUNT-1) randomized 2,539 adults with obesity and without diabetes to once-weekly tirzepatide 5, 10 or 15 mg or placebo for 72 weeks. Mean weight change was -15.0%, -19.5% and -20.9% across the three doses versus -3.1% with placebo, and about 91% of the 15 mg group lost at least 5% of body weight. Tirzepatide activates both the GIP and GLP-1 receptors, and like the other approved incretin peptides it is a licensed medicine given under medical supervision. Gastrointestinal effects were the most common adverse events.
Who this may not transfer to:Studied in adults with obesity of both sexes; the effect is specific to the licensed drug under medical supervision and does not transfer to unregulated peptides.
This is the strongest weight-loss result in the approved-peptide class, achieved with a prescribed and monitored drug. It says nothing about the fitness or anti-aging peptides sold as research chemicals.
The study · 1
Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · N Engl J Med 2022;387(3):205-216
Blood Sugar
Semaglutide lowered HbA1c about 0.7 to 1.0 points in type 2 diabetes
As a diabetes medicine, the GLP-1 peptide semaglutide brings long-term blood sugar down substantially and helps with weight at the same time. Insulin, the original peptide drug, is the other clear example of a peptide that treats disease.
Marso and colleagues (2016) randomized 3,297 adults with type 2 diabetes and high cardiovascular risk to semaglutide or placebo added to standard care for 104 weeks. HbA1c fell by about 0.7 to 1.0 percentage points more than placebo depending on dose, with weight loss and blood-pressure reduction. The trial was designed and powered as a cardiovascular safety study, and the glucose lowering is consistent with the wider GLP-1 receptor agonist class. Insulin, also a peptide, remains the defining example of a peptide hormone used as an established, life-sustaining drug.
Who this may not transfer to:Studied in adults with type 2 diabetes at high cardiovascular risk; the glucose effect is specific to the prescribed drug.
The approved GLP-1 and insulin peptides are prescribed and monitored for defined conditions. Their track record does not transfer to peptides bought for general fitness or anti-aging.
The study · 1
Marso et al., Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) · N Engl J Med 2016;375(19):1834-1844
Heart And Vascular
Semaglutide cut major cardiovascular events about 20% in people with heart disease
The approved GLP-1 peptides do more than lower weight and blood sugar; in large trials they reduce heart attacks, strokes and kidney decline. This is the strongest evidence in the whole peptide category, and it belongs to licensed drugs used under a doctor.
Lincoff and colleagues (2023, SELECT) randomized 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes to semaglutide 2.4 mg or placebo; the primary composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke fell with a hazard ratio of 0.80. Badve and colleagues (2025) pooled randomized trials of GLP-1 receptor agonists and reported consistent reductions in major cardiovascular events and adverse kidney outcomes across the class. These are outcome trials of prescription peptides, not the fitness or anti-aging compounds sold online.
Who this may not transfer to:Studied in adults with obesity and established heart disease; the outcome benefit is specific to licensed GLP-1 medicines.
This hard-outcome evidence is specific to approved GLP-1 medicines. Treat it as a marker of what a rigorously tested peptide drug can achieve, not as reassurance about peptides in general.
The studies · 2
Lincoff et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) · N Engl J Med 2023;389(24):2221-2232
Badve et al., Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials · Lancet Diabetes Endocrinol 2025
How it works
CJC-1295 raised blood GH and IGF-1 for days, a lab marker only
Growth-hormone-releasing peptides such as CJC-1295, ipamorelin and the GHRP compounds do reliably push up growth hormone and IGF-1 in the blood. That the blood markers move is established; that this makes anyone healthier, stronger or younger is a separate question the studies did not answer.
Teichman and colleagues (2006) gave escalating single and multiple doses of CJC-1295, a long-acting GHRH analogue, to healthy adults and measured a sustained rise in growth hormone and in IGF-1 lasting several days, with IGF-1 increasing markedly above baseline. The study measured hormone concentrations and safety, not body composition, strength, recovery or any clinical outcome. So the demonstrated effect is a change in laboratory markers, which is not the same as a benefit to the body.
Who this may not transfer to:Measured in healthy adult volunteers; only hormone levels were recorded, so the biomarker rise does not indicate a health gain.
A rise in GH and IGF-1 is what these peptides are sold for, but a moved biomarker is not a health gain. The same IGF-1 rise is also the mechanism behind the cancer-risk concern noted in the cautions.
The study · 1
Teichman et al., Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults · J Clin Endocrinol Metab 2006;91(3):799-805
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
BPC-157 speeds tendon and tissue healing in rats, with no completed human trial
The popular healing peptide BPC-157 has a substantial body of rodent research suggesting it speeds tissue and tendon repair. It has not been tested in a completed randomized human trial, so its use in people is experimental, and it is sold without approval.
Work from the Sikiric group and others reports that BPC-157 accelerates healing of tendon, muscle, gut and other tissues in rats and mice, with proposed effects on blood-vessel growth and healing pathways, summarized across reviews such as Seiwerth and colleagues (2021) and shown in models like the disabled myotendinous junction in rats (Japjec and colleagues, 2021). The entire persuasive dataset is preclinical. There is no completed randomized controlled trial in humans, so efficacy and safety in people are not established, and the compound is not an approved drug.
Who this may not transfer to:Evidence is from rat and mouse studies; there is no completed human trial to transfer from.
Rodent healing data is a reason to study a peptide, not a reason to inject it. Until human trials exist, BPC-157 should be read as a research compound, and buying it online adds the separate risks of purity and dosing covered in the cautions.
The studies · 2
Japjec et al., BPC-157 and tendon/ligament healing (animal) · Biomedicines 2021;9(11):1547
Seiwerth et al., BPC-157 in tissue healing and cytoprotection (review) · Front Pharmacol 2021;12:627533
TB-500 shows tissue-repair activity in preclinical work, untested in people
TB-500 is a fragment marketed from thymosin beta-4, a natural repair protein. Its regenerative effects are seen in cell and animal work, and it has no approved human use for recovery or anti-aging, so injecting it is experimental.
Thymosin beta-4 is an actin-binding peptide involved in cell migration and wound repair, and reviews such as Bock-Marquette and colleagues (2023) describe preclinical regenerative and anti-aging signals across injury and tissue-repair models. TB-500 is a synthetic fragment sold as a research peptide on that basis. The human evidence for the recovery and anti-aging uses it is marketed for is not established, and it is not an approved therapy.
Who this may not transfer to:Evidence is preclinical cell and animal work; no human outcome data exists to transfer from.
Preclinical repair biology is where a drug candidate starts, not where a consumer product should be. Treat TB-500 as untested in people for its marketed uses.
The study · 1
Bock-Marquette et al., Thymosin beta-4 and anti-aging regenerative therapies (review) · Int Immunopharmacol 2023;116:109741
Muscle And Strength
No human trial shows growth-hormone peptides build muscle, cut fat or slow aging
There is no good human trial showing that growth-hormone-releasing peptides build muscle, cut fat, speed recovery or extend healthspan. The human research stops at blood markers, so the athletic and anti-aging claims sold for these peptides rest on inference, not measured outcomes.
The best human evidence for peptides like CJC-1295 comes from short dose-finding studies that recorded growth hormone and IGF-1 concentrations and safety, such as Teichman and colleagues (2006), and did not measure body composition, strength, physical function or clinical endpoints. Claims that these peptides improve muscle, recovery or aging therefore extrapolate from a biomarker to an outcome, a step the trials did not take. Whether that extrapolation holds is not demonstrated in people.
Who this may not transfer to:Human data stops at hormone levels in healthy adults; no functional outcome was measured, so benefit is untested.
Judge these peptides by whether a trial measured the outcome someone actually wants, which for the anti-aging and fitness peptides has not happened. A hormone rise on a lab report is not evidence of a gain in the body.
The study · 1
Teichman et al., Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults · J Clin Endocrinol Metab 2006;91(3):799-805
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Skin And Hair
Copper peptide GHK-Cu acts on skin-repair pathways, with thin human skin data
Copper peptides such as GHK-Cu, used in topical skincare, have measurable activity on skin-repair pathways in the lab. The human cosmetic evidence is thin and mostly small, and a topical copper peptide is a far lower-stakes thing than an injected research peptide.
Reviews such as Dou and colleagues (2020) describe GHK and its copper complex GHK-Cu acting on collagen and skin-matrix genes, wound healing and antioxidant pathways in cell and animal systems. Human data is largely small cosmetic studies of topical products. As a topical ingredient the safety profile is more benign than injectable peptides, but the anti-aging skin benefit in people remains at the preliminary end, not established.
Who this may not transfer to:Mechanism is shown in the lab with small human cosmetic studies; a topical ingredient, far lower stakes than an injected peptide.
A topical copper peptide is a reasonable low-risk cosmetic to try on its own merits, judged by modest expectations. It is a different category from the injected peptides that carry the serious risks on this page.
The study · 1
Dou et al., The potential of GHK as an anti-aging peptide · Aging Pathobiol Ther 2020;2(1):58-61
How It Works
Peptides act as signals. A natural peptide hormone binds a receptor on a cell and sets off a response. Insulin drives cells to take up glucose. GLP-1 signals fullness to the brain and prompts the pancreas to release insulin. A synthetic peptide drug is built to copy or trigger one of these signals. Semaglutide is a modified copy of GLP-1 that resists breakdown, so it keeps signaling for a week.
The mechanisms differ by peptide. Growth hormone peptides prompt the pituitary to release the body's own growth hormone, which then raises IGF-1, the downstream growth signal. BPC-157 is a fragment patterned on a protein found in stomach juice, proposed to aid healing through effects on blood-vessel growth.
Peptides are proteins, and the gut digests proteins, so most of these compounds do not survive being swallowed. They are taken by injection. The approved GLP-1 peptides are the engineered exception, given as a weekly shot or, in one case, a specially formulated daily tablet. For the research and anti-aging peptides, injection is the norm. An unverified substance at an unknown dose goes into your body, a hazard separate from whether the peptide works.
With a gray-market vial you are injecting something whose identity and dose you cannot confirm, a risk that stands apart from whether the peptide even works.
How to Think About It
To place any peptide, start by asking whether it is an approved drug or a research chemical.
Before anything else, place the peptide. GLP-1 medicines and insulin are approved, prescription peptide drugs. BPC-157, TB-500, the growth hormone peptides, and melanotan are not approved and are sold as research chemicals.
Treat them as experimental: no human trial has shown a benefit to the body, and long-term safety is unknown.
Research-labeled peptides come with no manufacturing controls, and no batch is tested before it ships.
The GLP-1 medicines are prescribed, with the dose titrated over weeks so side effects stay manageable. A clinician can tell you whether an approved peptide fits your situation and point you away from the unregulated ones.
Go Deeper
The fitness peptides promise muscle and recovery. These levers have the human track record they lack:
- Weight and metabolic health, where the approved GLP-1 peptides fit.
- Creatine, a long human track record for muscle and strength, the outcome the injections claim.
- Protein and muscle, a plainer lever than any injected peptide.
- Collagen, the one peptide most people already take by mouth.
The Chinese Medicine View
Peptides are a product of modern biochemistry, isolated and synthesized in the last 100 years. No classical Chinese text assigns a channel, a temperature, or a flavor to a peptide, and no traditional formula contains one. The Kidney in Chinese medicine stores Jing, the deep constitutional reserve that governs growth, development, and the vitality a body draws on across a lifetime. Jing is understood to thin with age. The anti-aging and growth peptides are sold, loosely, for the same idea: topping up the body's growth and repair signals as they decline.
The tradition adds a caution. Forcing growth is understood to draw the reserve down, and driving a system harder than its constitution allows is understood to wear it out. That is a loose echo of the cancer caution below, where pushing IGF-1 up year after year carries its own risk, but the echo is a way of thinking about restraint, not evidence that Jing depletion and IGF-1-driven cancer risk are the same mechanism.
Cautions
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
GLP-1 drugs commonly cause nausea and other gut effects, enough to stop some people
In the STEP 1 trial of semaglutide 2.4 mg (Wilding and colleagues, 2021), gastrointestinal effects, chiefly nausea, diarrhea, vomiting and constipation, were the most common adverse events and the most common reason for discontinuation. These effects are usually dose-related and managed by slow dose escalation under medical supervision. This is a documented downside of a licensed peptide, distinct from the unknown risks of unregulated ones.Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Grey-market peptides carry wrong doses, missing ingredient and contamination
Janvier and colleagues (2018) review the falsification of biotechnology and peptide drugs, documenting products with incorrect content, degraded or absent active ingredient, and impurities, and warn that grey-market supply lets these reach users directly. Because performance and anti-aging peptides are typically sold labeled for research use only, not as approved medicines, no regulator verifies identity, dose, sterility or purity of a given batch. Injecting such a product means accepting an unknown substance at an unknown dose.Janvier et al., Falsification of biotechnology drugs: current dangers and/or future disasters?
Higher IGF-1 tracks with more prostate and premenopausal breast cancer
Renehan and colleagues (2004) pooled case-control studies, including studies nested in cohorts, in a systematic review and meta-regression and found that higher circulating IGF-1 concentrations were associated with increased risk of prostate cancer and premenopausal breast cancer, with related patterns for IGF binding protein 3. The data are observational, so they show association, not proof that raising IGF-1 causes cancer, and no one has run a long trial of GH-axis peptides measuring cancer outcomes. Given that these peptides are used precisely to elevate IGF-1, the association is a substantive safety concern.Renehan et al., Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
Melanotan II tanning injections are tied to priapism and a kidney clot in case reports
Case reports describe serious harms from melanotan II bought and self-injected outside medical care: Dreyer and colleagues (2019) report melanotan-induced priapism requiring intervention, and Peters and colleagues (2020) report renal infarction associated with its use, reviewing related literature. Reported effects also include nausea, flushing and darkening or change of melanocytic naevi, which can obscure early melanoma. The product is not an approved medicine, and dose and purity of online supply are uncontrolled.Dreyer et al., Melanotan-induced priapism: a hard-earned tan (case report)Peters et al., Melanotan II: a possible cause of renal infarction (case report)
Unregulated products and contamination
Most performance and anti-aging peptides are made and shipped outside pharmaceutical controls. What is in a given vial is uncertain, and analyses of falsified peptide products have found wrong doses, missing active ingredient, and contamination. That uncertainty is what gets injected.
Injecting a grey market product
Beyond what the peptide does, self-injecting a non-sterile or mislabeled product carries its own risks: infection, abscess, and injection-site reactions. No online fitness or anti-aging peptide has been tested for safe self-administration. Dosing advice comes from online forums, and no trial has established a safe dose.
Growth hormone peptides and the cancer concern
The growth hormone peptides work by raising IGF-1, and higher IGF-1 has been linked in large observational studies to a higher risk of some cancers. No trial has measured cancer outcomes for these peptides, so raising IGF-1 for years remains an open risk.
Most of these peptides are not FDA-approved
Apart from the licensed GLP-1 medicines and insulin, the peptides here are not approved drugs. Regulators have acted against several sold in the compounding and research-chemical market. Not being approved means no authority has judged them safe or effective for the uses they are sold for. No manufacturer is accountable for what a batch contains.
Have the underlying problem checked
A clinician can give you an read on the risk and the evidence for any peptide. They can also check whether the symptom you are trying to self-treat needs care.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Are peptides a safe shortcut to muscle or a longer life?
For most sold that way, no. The claim borrows credibility from a few approved peptide drugs, then applies it to compounds whose human evidence does not exist yet. BPC-157, TB-500, and the growth peptides have not been shown to do in people what they promise.
Does BPC-157 heal injuries in people?
Not in a completed human trial. The healing evidence is preclinical: tendon, muscle, and gut repair seen in rats, not yet tested in a randomized human study.
Do growth hormone peptides build muscle or slow aging?
No. They move the blood markers, as the body explains, but nothing past that has been shown, not muscle, not fat loss, not a longer life. Pushing those markers up over years is also the cancer concern above.
Are the online peptides legal?
They sit in a grey area. Many are labeled "research use only," a phrase that sidesteps drug approval without claiming the product is safe.
Which peptides have real evidence behind them?
Two. The GLP-1 medicines are the clear modern case. The other is insulin: the first peptide drug, it has sustained lives for 100 years.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 16 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.